| Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy C Karacin, B Oksuzoglu, A Demirci, M Keskinkılıç, NK Baytemür, F Yılmaz, ... BMC cancer 23 (1), 136, 2023 | 11 | 2023 |
| Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: a multicenter study HÇ Yıldırım, E Mutlu, E Chalabiyev, M Özen, M Keskinkılıç, S Ön, A Çelebi, ... The Breast 66, 85-88, 2022 | 7 | 2022 |
| Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis M Kanbay, AB Yildiz, D Siriopol, S Vehbi, NB Hasbal, YE Kesgin, ... International Urology and Nephrology 55 (4), 1025-1032, 2023 | 6 | 2023 |
| Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group E Aytaç, F Aslan, B Çicek, S Erdamar, B Gürses, K Güven, O Falay, ... The Turkish Journal of Gastroenterology 30 (7), 584, 2019 | 5 | 2019 |
| Is virtual nutritional counseling efficacious for cancer patients during the COVID-19 pandemic? D Baş, Ö Sönmez, ES Koç, ÖM Celayir, L Hajhamidiasl, E Tontaş Journal of Telemedicine and Telecare 30 (1), 79-89, 2024 | 2 | 2024 |
| The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer … HÇ Yıldırım, Y Kutlu, E Mutlu, MB Aykan, M Korkmaz, S Yalçın, T Şakalar, ... International Journal of Clinical Oncology, 1-8, 2024 | 1 | 2024 |
| Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement E Aytaç, L Özer, B Baca, E Balık, Y Kapran, OC Taşkın, BO Uluç, ... The Turkish Journal of Gastroenterology 33 (8), 627, 2022 | 1 | 2022 |
| Evaluation of Human Epidermal Growth Factor Receptor 2 Overexpression, Clinicopathological Characteristics, and Factors Affecting Survival in Gastric Cancer OM Celayir, F Selcukbiricik, C Tanik, Y Altuntas The Medical Bulletin of Sisli Etfal Hospital 55 (2), 224, 2021 | 1 | 2021 |
| The Effects of Initial Symptoms on the Prognosis in Patients with Stomach Cancer M Celayir, FS Biricik, A Bilici Haseki Tip Bulteni 53 (3), 2015 | 1 | 2015 |
| Mide Kanserli Hastaların Başvuru Semptomlarının Prognoza Etkisi M Celayir, FS Biricik, A Bilici Medical Bulletin of Haseki/Haseki Tip Bulteni 53 (3), 2015 | 1 | 2015 |
| Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy C Karacin, B Oksuzoglu, A Demirci, M Keskinkılıç, NK Baytemür, F Yılmaz, ... BMC cancer 23 (1), 192, 2023 | | 2023 |
| Yumuşak doku sarkomlarında sistemik tedavi L Özer, ÖM Celayir, M Sungur | | |
| Association between high initial CEA, CA 19-9 levels and HER-2 status and their prognostic values on overall survival in metastatic gastric cancer F Selcukbiricik, K Erturk, E Balık, BB Kuvvet, M Celayir, F Babashov, ... | | |
| ÖZGÜN ARAŞTIRMA M Celayir, FS Biricik, A Bilici | | |
| ASIAN ACADEMIC RESEARCH JOURNAL OF MULTIDISCIPLINARY OF COLON, M CELAYIR, F SELCUKBIRICIK, A BILICI, A OZAGARI | | |
| Evaluation of HER2 overexpression, clinicopathological characteristics, and factors affecting survival in gastric cancer OM Celayir, F Selcukbiricik, C Tanik, Y Altuntas The Medical Bulletin of Sisli Etfal Hospital 55 (2), 0 | | |
